CPhI Online is the largest global marketplace in the pharma ingredients industry
Clinical & Commercial Drug Product Manufacturing: Outsourcing Advice from a CDMO
Taking a sterile drug product from clinical to commercial scale brings unique challenges. In this article, LLS Health investigates ways to mitigate scale-up challenges and achieve success.
The point in drug development where a project moves from the clinical to the commercial stage often brings unforeseen challenges that may cause delays in bringing a drug product to market. Chief among these is a lack of global capacity and infrastructure to successfully scale up sterile products to commercial levels.
Drug shortages, especially for sterile injectables, have been a pressing issue for several years. While pharmaceutical CDMOs have invested in additional manufacturing capacity, market estimates still predict that demand for aseptic manufacturing services will outpace supply in the next two years. In the rapidly expanding cell and gene therapy market, for example, manufacturing capacity shortfalls are estimated to be 5 times the current demand and will continue to grow in coming years. Drug developers report difficulty finding CDMOs with both clinical and commercial manufacturing expertise to help them get to market.
In addition, events of the last 12 months have seen COVID-19 vaccines and treatments prioritized by larger pharma companies and their manufacturing partners. This has further reduced available production capacity to commercialize new therapies.
While around 80% of clinical trials were delayed or put on hold during 2020, many pharmaceutical executives estimate that clinical trial activity will return to pre-COVID levels in 2021. With all of this in mind, what can drug developers do to mitigate manufacturing capacity issues and ensure that their drug programs are given the priority they deserve?
Scale-Up Challenges for Sterile Drug Products
There are several reasons why manufacturing capacity is limited at the clinical-to-commercial stage.
Lack of Infrastructure and Expertise
Companies looking to commercialize a sterile drug product need access to manufacturing infrastructure and a team capable of scaling up from small clinical batches to commercial production. Meeting key deadlines and going to market depends heavily on this team’s ability to troubleshoot and adapt to processing challenges. However, many drug developers do not have this capability in-house.
Small start-up or virtual companies often rely on partners for their manufacturing needs. While they may find a contract development and manufacturing organization (CDMO) that can manufacture , transitioning to can be challenging or impossible if the partner is not equipped for registration batches and beyond.
While transitioning to a separate CDMO for commercial production is possible, it can delay a project with additional qualification and training activities. Ideally, smaller companies can simplify the process by putting their lead candidate in the hands of a single partner that understands the needs of both clinical and commercial supply.
Larger companies, meanwhile, may not have the flexibility or available capacity to ramp up production for new drug products. Cleanroom space is often dedicated to existing, marketed products, and production lines may not be equipped for low-volume products, such as .
In cases like these, a CMO with flexible cleanroom space and the ability to work with a range of batch sizes plays a critical role in commercialization.
Supply Chain Obstacles
The prioritization of COVID-19 vaccines has further reduced manufacturing capacity at the clinical-to-commercial stage for new drug products. In addition to decreased capacity, the pandemic has also restricted the availability of supplies of vital components and resources, such as vials and other packaging, as well as intermediates and raw materials.
This is a universal issue across all of pharma, and it requires manufacturing organizations to maintain robust supply chains and plan ahead to mitigate risk.
Overcoming the Hurdles
Given these potential challenges, it is no surprise that drug developers – both large multinationals and smaller virtual businesses – may feel daunted by the prospect of bringing a treatment to market in the current climate.
In times like these, it’s more important than ever to partner with CDMOs that are transparent, attentive, and able to adapt to your project needs. These expert partners have the experience, resources, and capacity, as well as the reliable supply chain, to prioritize your project and bring it from clinical to commercial.
To find the right partner with the right capabilities for your needs, it’s important to ask them a few key questions:
- Do you have the availability and capacity to work on my project straight away?
- How have you secured your supply of raw materials against potential shortages?
- Will my project be a priority for your team?
- Do you have a minimum batch size?
- Does your site have the flexibility to increase production volumes as my project progresses?
Finding the Right Support
At the CDMO Division of LLS Health, we are proud of our ability to answer many of these questions in the affirmative.
We’ve equipped our FDA-ready facility with an attentive team and flexible capacity to support the transfer of your project from clinical to commercial. Our manufacturing facility has , and whether you are developing large or small molecule product, we are here to help you bring your project to market as quickly as possible.
We have also taken steps to secure our procurement of raw materials and other vital components to safeguard against any shortages. As a member of the Berkshire Hathaway family of companies, we have access to a flexible and responsive global supply chain capable of mitigating the impact of supply shocks. You can also trust us as a long-term partner who will be here to meet your production needs for years to come.
Working with LLS Health, you can be confident that you have the support you need to hit your project milestones on time and deliver your product to market.
- Drug Shortages | The Pew Charitable Trusts. https://www.pewtrusts.org/en/research-and-analysis/reports/2017/01/drug-shortages
- Answering the CDMO shortage: A new paradigm for drug development – Drug Discovery and Development. https://www.drugdiscoverytrends.com/answering-the-cdmo-shortage-a-new-paradigm-for-drug-development/
- 17th Annual 2020 Top Bioprocessing TRENDS White Paper BioPlan 20200713B – BioPlan Associates. https://www.bioplanassociates.com/article/biopharma-manufacturing-trends-2020/17th-annual-2020-top-bioprocessing-trends-white-paper-bioplan-20200713b/
- van Dorn A. COVID-19 and readjusting clinical trials. . 2020;396(10250):523-524. doi:10.1016/S0140-6736(20)31787-6
- Q3 2020 Pharma Services Sector Snapshot – Bourne Partners. https://bourne-partners.com/sector-report/q3-2020-pharma-services-sector-snapshot/
Sponsored Content Thermo Fisher Scientific Opens cGMP Plasmid DNA Manufacturing Facility in Carlsbad, CaliforniaResponding to critical market capacity constraints, Thermo Fisher announces the official opening of new 67,000 sqft cGMP plasmid DNA manufacturing facility in Carlsbad, CA. This site expands clinical and commercial capabilities for cGMP plasmid DNA use...
Sponsored Content Biocatalysis: An Indispensable Tool for Synthesis of Active Pharmaceutical IngredientsBiocatalytic processing offers a wealth of advantages and should be evaluated during early-stage drug development for its potential to improve yields, increase efficiency, and support greener manufacturing.
Catch up on the latest trends and developments in orally disintegrating tablet (ODT) formulation development
Shawn Branning, Global Strategic Marketing Manager at IFF – Pharma Solutions
Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and...
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected...
Watch this Learning Lab video presented by Chris McPherson, Principal Scientist, DS Manufacturing, Samsung Biologics, which details how CDMOs have reacted to the challenging ‘Black Swan’ event that is the COVID-19 pandemic by initiatin...
Position your company at the heart of the global Pharma industry with a CPhI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPhI events
An easy-to-use platform with a detailed dashboard showing your leads and performance